Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Recce Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RCE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: RCE's weekly volatility has decreased from 13% to 7% over the past year.
7 Day Return
1 Year Return
Return vs Industry: RCE exceeded the Australian Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: RCE exceeded the Australian Market which returned 35.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Recce Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Is The Ownership Structure Like For Recce Pharmaceuticals Ltd (ASX:RCE)?
2 months ago | Simply Wall StRecce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans
3 months ago | Simply Wall StNeed To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares
Is Recce Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RCE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RCE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RCE is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: RCE is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RCE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RCE is overvalued based on its PB Ratio (8.2x) compared to the AU Pharmaceuticals industry average (3.1x).
How is Recce Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Recce Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Recce Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RCE is currently unprofitable.
Growing Profit Margin: RCE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RCE is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.
Accelerating Growth: Unable to compare RCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).
Return on Equity
High ROE: RCE has a negative Return on Equity (-56.48%), as it is currently unprofitable.
How is Recce Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RCE's short term assets (A$24.1M) exceed its short term liabilities (A$1.3M).
Long Term Liabilities: RCE's short term assets (A$24.1M) exceed its long term liabilities (A$116.3K).
Debt to Equity History and Analysis
Debt Level: RCE is debt free.
Reducing Debt: RCE has no debt compared to 5 years ago when its debt to equity ratio was 2.1%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RCE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: RCE has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 28.9% each year.
What is Recce Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RCE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RCE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RCE's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD167.86K) is below average for companies of similar size in the Australian market ($USD287.14K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Management: RCE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: RCE's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.2%.
Recce Pharmaceuticals Ltd's company bio, employee growth, exchange listings and data sources
- Name: Recce Pharmaceuticals Ltd
- Ticker: RCE
- Exchange: ASX
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$191.156m
- Shares outstanding: 173.78m
- Website: https://www.recce.com.au
- Recce Pharmaceuticals Ltd
- Gateway Tower
- Level 36
- New South Wales
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 11:14|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.